Stock Events

Stock Events

Assembly Biosciences 

$29.65
0
+$3.01+11.3% Today

Statistics

Day High
29.65
Day Low
26.63
52W High
-
52W Low
-
Volume
245
Avg. Volume
-
Mkt Cap
468.97M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.86
-0.11
0.64
1.39
Expected EPS
-0.77
Actual EPS
N/A

Financials

-140.87%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
57.04MRevenue
-80.35MNet Income

Analyst Ratings

$50.00Average Price Target
The highest estimate is 50.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ASMB.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a leading biopharmaceutical company that competes with Assembly Biosciences in the development of treatments for viral diseases, including hepatitis B, which is a key focus area for Assembly Biosciences.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in the pharmaceuticals sector focusing on therapies for chronic diseases, including hepatitis, directly competing with Assembly Biosciences' hepatitis B therapeutic development.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is involved in the discovery, development, and marketing of drugs for infectious diseases, including hepatitis B, making it a competitor to Assembly Biosciences.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is a global biopharmaceutical company with a portfolio that includes viral infection treatments, competing with Assembly Biosciences in the hepatitis B market.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals incorporates innovative drug discovery and development, particularly in treating chronic diseases, which puts it in competition with Assembly Biosciences in the field of hepatitis B.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap5.86B
Arrowhead Pharmaceuticals focuses on developing medicines for intractable diseases by silencing the genes that cause them, including hepatitis B, making it a direct competitor to Assembly Biosciences.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for infectious diseases, including hepatitis B, positioning it as a competitor to Assembly Biosciences.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is pioneering RNA interference (RNAi) therapeutics, with a focus on liver diseases including hepatitis B, competing with Assembly Biosciences' approach.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics focuses on genomic medicine, including gene editing and gene therapy for liver diseases like hepatitis B, making it a competitor to Assembly Biosciences.

About

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Show more...
CEO
ISIN
US0453962070

Listings

XNAS
US
ASMB
F
DE
V7B.F
BOATS
BOATS
ASMB.BOATS

0 Comments

Share your thoughts

FAQ

What is Assembly Biosciences stock price today?▼
The current price of ASMB.BOATS is $29.65 USD — it has increased by +11.3% in the past 24 hours. Watch Assembly Biosciences stock price performance more closely on the chart.
What is Assembly Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Assembly Biosciences stocks are traded under the ticker ASMB.BOATS.
What is Assembly Biosciences market cap?▼
Today Assembly Biosciences has the market capitalization of 468.97M
When is the next Assembly Biosciences earnings date?▼
Assembly Biosciences is going to release the next earnings report on May 07, 2026.
What were Assembly Biosciences earnings last quarter?▼
ASMB.BOATS earnings for the last quarter are 1.39 USD per share, whereas the estimation was -0.86 USD resulting in a +262.69% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Assembly Biosciences revenue for the last year?▼
Assembly Biosciences revenue for the last year amounts to 57.04M USD.
What is Assembly Biosciences net income for the last year?▼
ASMB.BOATS net income for the last year is -80.35M USD.
When did Assembly Biosciences complete a stock split?▼
Assembly Biosciences has not had any recent stock splits.